Indications And Dose
Maintenance of moderate-to-severe chronic obstructive pulmonary disease ▶BY INHALATION OF POWDER ▶Adult: 1 inhalation once daily, dose should be taken at the same time each day
PDF page 301
Loading InternPractice…
Drug reference
Maintenance of moderate-to-severe chronic obstructive pulmonary disease ▶BY INHALATION OF POWDER ▶Adult: 1 inhalation once daily, dose should be taken at the same time each day
PDF page 301
Convulsive disorders. pulmonary tuberculosis. thyrotoxicosis
PDF page 301
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (February 2018) that fluticasone furoate with umeclidinium and vilanterol (as trifenatate) (Trelegy ® Ellipta ®) is accepted for restricted use within NHS Scotland for the maintenance treatment in adults with severe chronic obstructive pulmonary disease (forced expiratory volume in one second [FEV1] <50% predicted normal).
PDF page 301
→Appendix 1: beta2 agonists. corticosteroids. umeclidinium
PDF page 301
▶Common or very common Arthralgia. back pain. constipation. cough. increased risk of infection. oropharyngeal pain ▶Uncommon Bone fracture. dry mouth. dysphonia ▶Frequency not known Vision disorders Respiratory system
PDF page 301
Manufacturer advises caution in moderate to severe impairment.
PDF page 301
There can be variation in the licensing of different medicines containing the same drug. Inhalation powder ▶Trelegy Ellipta (GlaxoSmithKline UK Ltd) A Vilanterol (as Vilanterol trifenatate) 22 microgram per 1 dose, Umeclidinium bromide 65 microgram per 1 dose, Fluticasone furoate 92 microgram per 1 dose Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler | 30 dose P £44.50 eiiii F 264
PDF page 301
Patients or carers should be given advice on appropriate inhaler technique.
PDF page 301
1 inhalation once daily, dose should be taken at
First-line fragment. Read the complete Indications and Dose section above.
PDF page 301